SCHEMBL20280950

SCHEMBL20280950

COc1cc2nc(-c3cccc4cccnc34)nc(NCCNC(=N)N)c2cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.45
CYP2D6 P10635 3/20 0.45
ALDH1A1 P00352 3/20 0.45
ALOX15 P16050 2/20 0.45
KDM4E B2RXH2 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
KDM1A O60341 2/20 0.41
EHMT2 Q96KQ7 2/20 0.41
RCOR1 Q9UKL0 2/20 0.41
CNR2 P34972 1/20 0.41
POLB P06746 2/20 0.40
HTT P42858 1/20 0.40
CYP3A4 P08684 2/20 0.40
USP2 O75604 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20266993 0.87 SYK (0.45) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL20280935 0.82 PDE4A (0.59) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL20281074 0.81 PGK1 (0.57) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL20280938 0.80 GLRA3 (0.49) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL20280942 0.79 CYP1A2 (0.46) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL20281126 0.79 LATS1 (0.41) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL26203646 0.79 LATS1 (0.41) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL20280944 0.77 CYP1A2 (0.60) CYP1A2CYP2D6ALDH1A1ALOX15KDM4E
SCHEMBL20267023 0.72 PDGFRB (0.46) CNR2MAPTLMNAMEN1KMT2A
SCHEMBL20266999 0.72 PDGFRB (0.43) ALDH1A1CNR2POLBTSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718609-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-08-08 US disclosed
US-11718609-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-08-08 US disclosed
US-20210130338-A1 Heparanase Inhibitors and Use Thereof Beta Therapeutics Pty Ltd (AU) 2021-05-06 US disclosed
US-20200093852-A1 Methods of Treating Ocular Disorders Beta Therapeutics Pty Ltd (AU) 2020-03-26 US disclosed
WO-2018107226-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2018-06-21 WO disclosed
WO-2018107200-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2018-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093852-A1 Methods of Treating Ocular Disorders ALDH1A2, HPSE, RB1 CYP1A2 4837/4885CYP2D6 4841/4885ALDH1A1 2240/4885
US-20210130338-A1 Heparanase Inhibitors and Use Thereof HPSE, HEXD, ENGASE CYP1A2 1462/4885CYP2D6 1130/4885ALDH1A1 2194/4885
US-11718609-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE CYP1A2 1462/4885CYP2D6 1130/4885ALDH1A1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.